LentiBOOST® is a universally acting (receptor independent) adjuvant that can be applied to a wide range of clinically relevant cells. It is commonly used in ex vivo cell therapy, both for stem cells and in the T cell space including CAR-T and TCR. Its underlying mode of action allows improved transduction of many further cell types including CD34+ hematopoietic stem cells (HSCs), B cells and NK cells. LentiBOOST® is currently included in more than 20 Phase III and I/II clinical trials. 

Pharma-grade LentiBOOST® can be used in all development applications through to late-stage preclinical. For our licensees, we provide GMP material for clinical trials and the commercialization phase. SIRION’s liquid GMP LentiBOOST® formulation complies with Eur. Pharm and USP, and we ensure stable supply of the GMP material for research and commercial stage programs.

We have developed a licensing strategy for LentiBOOST® that allows research hospitals to apply this technology on a royalty-free basis.